| Literature DB >> 30668558 |
Aolin Yang1, Qingqing Lv1, Feng Chen2, Difei Wang2, Ying Liu3, Wanying Shi1.
Abstract
BACKGROUND In recent years, many studies on vitamin D have been published. We combed these data for hot spot analyses and predicted future research topic trends. MATERIAL AND METHODS Articles (4625) concerning vitamin D published in the past 3 years were selected as a study sample. Bibliographic Items Co-occurrence Matrix Builder (BICOMB) software was used to screen high-frequency Medical Subject Headings (MeSH) terms and construct a MeSH terms-source article matrix and MeSH terms co-occurrence matrix. Then, Graphical Clustering Toolkit (gCLUTO) software was employed to analyze the matrix by double-clustering and visual analysis to detect the trends on the subject. RESULTS Ninety high-frequency major MeSH terms were obtained from 4625 articles and divided into 5 clusters, and we generated a visualized matrix and a mountain map. Strategic coordinates were established by the co-occurrence matrix of the MeSH terms based on the above classification, and the 5 clusters described above were further divided into 7 topics. We classified the vitamin D-related diseases into 12 categories and analyzed their distribution. CONCLUSIONS The analysis of strategic coordinates revealed that the epidemiological study of vitamin D deficiency and vitamin D-related diseases is a hot research topic. The use of vitamin D in the prevention and treatment of some diseases, especially diabetes, was found to have a significant potential future research value.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30668558 PMCID: PMC6350455 DOI: 10.12659/MSM.913026
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
High-frequency major MeSH terms from the included publications on vitamin D (n=76 125).
| No. | MeSH terms | Frequency n (% | Cumulative percentage (%) |
|---|---|---|---|
| 1 | Humans | 4094 (5.38) | 5.38 |
| 2 | Female | 2848 (3.74) | 9.12 |
| 3 | Male | 2459 (3.23) | 12.35 |
| 4 | Vitamin D/blood | 2087 (2.74) | 15.09 |
| 5 | Vitamin D/analogs and derivatives | 1613 (2.12) | 17.21 |
| 6 | Middle-aged | 1495 (1.96) | 19.17 |
| 7 | Adult | 1475 (1.94) | 21.11 |
| 8 | Aged | 1067 (1.40) | 22.51 |
| 9 | Vitamin D deficiency/blood | 903 (1.19) | 23.70 |
| 10 | Dietary supplements | 857 (1.13) | 24.83 |
| 11 | Animals | 834 (1.10) | 25.92 |
| 12 | Young adult | 644 (0.85) | 26.77 |
| 13 | Vitamin D/administration & dosage | 641 (0.84) | 27.61 |
| 14 | Adolescent | 563 (0.74) | 28.35 |
| 15 | Risk factors | 553 (0.73) | 29.07 |
| 16 | Vitamin D deficiency/epidemiology | 513 (0.67) | 29.75 |
| 17 | Cross-sectional studies | 499 (0.66) | 30.40 |
| 18 | Vitamin D deficiency/complications | 490 (0.64) | 31.05 |
| 19 | Vitamin D/therapeutic use | 481 (0.63) | 31.68 |
| 20 | Child | 437 (0.57) | 32.25 |
| 21 | Vitamin D/metabolism | 411 (0.54) | 32.79 |
| 22 | Vitamin D deficiency/drug therapy | 366 (0.48) | 33.27 |
| 23 | Biomarkers/blood | 360 (0.47) | 33.75 |
| 24 | Aged, 80 and over | 359 (0.47) | 34.22 |
| 25 | Prospective studies | 353 (0.46) | 34.68 |
| 26 | Vitamin D/pharmacology | 339 (0.45) | 35.13 |
| 27 | Treatment outcome | 323 (0.42) | 35.55 |
| 28 | Pregnancy | 317 (0.42) | 35.97 |
| 29 | Case-control studies | 315 (0.41) | 36.38 |
| 30 | Prevalence | 305 (0.40) | 36.78 |
| 31 | Child, preschool | 276 (0.36) | 37.15 |
| 32 | Cholecalciferol/administration and dosage | 269 (0.35) | 37.50 |
| 33 | Double-blind method | 268 (0.35) | 37.85 |
| 34 | Vitamin D Deficiency/diagnosis | 263 (0.35) | 38.20 |
| 35 | Seasons | 260 (0.34) | 38.54 |
| 36 | Receptors, calcitriol/metabolism | 259 (0.34) | 38.88 |
| 37 | Body mass index | 253 (0.33) | 39.21 |
| 38 | Parathyroid hormone/blood | 252 (0.33) | 39.54 |
| 39 | Calcifediol/blood | 246 (0.32) | 39.86 |
| 40 | Vitamins/therapeutic use | 244 (0.32) | 40.19 |
| 41 | Mice | 241 (0.32) | 40.50 |
| 42 | Calcitriol/pharmacology | 234 (0.31) | 40.81 |
| 43 | Infant | 230 (0.30) | 41.11 |
| 44 | Follow-up studies | 213 (0.28) | 41.39 |
| 45 | Cohort studies | 212 (0.28) | 41.67 |
| 46 | Vitamins/administration and dosage | 205 (0.27) | 41.94 |
| 47 | Receptors, calcitriol/genetics | 196 (0.26) | 42.20 |
| 48 | Calcium/blood | 195 (0.26) | 42.45 |
| 49 | Dose-response relationship, drug | 189 (0.25) | 42.70 |
| 50 | Retrospective studies | 180 (0.24) | 42.94 |
| 51 | Time factors | 177 (0.23) | 43.17 |
| 52 | Cholecalciferol/therapeutic use | 172 (0.23) | 43.40 |
| 53 | Infant, newborn | 161 (0.21) | 43.61 |
| 54 | Sunlight | 155 (0.20) | 43.81 |
| 55 | Cholecalciferol/pharmacology | 152 (0.20) | 44.01 |
| 56 | Severity of Illness Index | 152 (0.20) | 44.21 |
| 57 | Vitamin D deficiency/prevention and control | 152 (0.20) | 44.41 |
| 58 | Nutritional status | 146 (0.19) | 44.60 |
| 59 | Rats | 142 (0.19) | 44.79 |
| 60 | Diet | 138 (0.18) | 44.97 |
| 61 | Logistic models | 132 (0.17) | 45.14 |
| 62 | Vitamin D | 131 (0.17) | 45.31 |
| 63 | Vitamins/pharmacology | 129 (0.17) | 45.48 |
| 64 | Surveys and Questionnaires | 127 (0.17) | 45.65 |
| 65 | Cells, cultured | 122 (0.16) | 45.81 |
| 66 | Calcitriol/analogs and derivatives | 121 (0.16) | 45.97 |
| 67 | Age factors | 119 (0.16) | 46.13 |
| 68 | Bone density | 115 (0.15) | 46.28 |
| 69 | Disease models, animal | 114 (0.15) | 46.43 |
| 70 | Cell line, tumor | 114 (0.15) | 46.58 |
| 71 | Vitamins/blood | 114 (0.15) | 46.73 |
| 72 | Randomized Controlled Trials as Topic | 114 (0.15) | 46.88 |
| 73 | Prognosis | 114 (0.15) | 47.03 |
| 74 | Polymorphism, single-nucleotide | 112 (0.15) | 47.17 |
| 75 | Incidence | 110 (0.14) | 47.32 |
| 76 | Vitamin D Deficiency/metabolism | 110 (0.14) | 47.46 |
| 77 | Odds ratio | 104 (0.14) | 47.60 |
| 78 | Vitamin D Deficiency/etiology | 102 (0.13) | 47.73 |
| 79 | Linear models | 101 (0.13) | 47.87 |
| 80 | Multivariate analysis | 101 (0.13) | 48.00 |
| 81 | Cell line | 98 (0.13) | 48.13 |
| 82 | Calcitriol/administration and dosage | 95 (0.12) | 48.25 |
| 83 | Calcitriol/therapeutic use | 94 (0.12) | 48.38 |
| 84 | Ultraviolet rays | 94 (0.12) | 48.50 |
| 85 | Sex factors | 94 (0.12) | 48.62 |
| 86 | Vitamin D Deficiency/physiopathology | 94 (0.12) | 48.75 |
| 87 | Insulin resistance | 92 (0.12) | 48.87 |
| 88 | Diabetes Mellitus, Type 2/blood | 92 (0.12) | 48.99 |
| 89 | Calcium/metabolism | 91 (0.12) | 49.11 |
| 90 | Bone Density/drug effects | 90 (0.12) | 49.23 |
Proportion of the frequency among 76 125 appearances.
High-frequency major MeSH terms-source articles matrix (localized).
| No. | Major MeSH terms | PMID of source article | ||||
|---|---|---|---|---|---|---|
| 21642832 | 23109511 | 23784946 | … | 29677309 | ||
| 1 | Humans | 1 | 1 | 0 | … | 1 |
| 2 | Female | 0 | 0 | 0 | … | 1 |
| 3 | Male | 0 | 1 | 0 | … | 1 |
| 4 | Vitamin D/blood | 0 | 0 | 0 | … | 0 |
| … | … | … | … | … | … | … |
| 89 | Calcium/metabolism | 0 | 0 | 0 | … | 0 |
| 90 | Bone Density/drug effects | 0 | 0 | 0 | … | 0 |
Descriptive and discriminating features and representative articles.
| Descriptive and discriminating features | ||||
|---|---|---|---|---|
| Descriptive | 26826045 | 25300588 | 26845632 | 27488178 |
| Discriminating | 26868944 | 27488178 | 26826045 | 26291437 |
| Descriptive | 26794222 | 27998003 | 27154546 | 26630444 |
| Discriminating | 26794222 | 27998003 | 27154546 | 26630444 |
| Descriptive | 27413130 | 28323044 | 28615261 | 27717236 |
| Discriminating | 27413130 | 28323044 | 27717236 | 26173598 |
| Descriptive | 28331054 | 26628439 | 26861385 | 28333101 |
| Discriminating | 28331054 | 26628439 | 27776564 | 26938997 |
| Descriptive | 25901090 | 26184826 | 28882871 | 26498119 |
| Discriminating | 25901090 | 26184826 | 28882871 | 26009498 |
ISim – Internal Similarity; ESim – External Similarity.
Size: number of cluster objects;
PubMed Unique Identifiers of literature.
A co-word matrix of high-frequency major MeSH terms (localized).
| No. | Major MeSH terms | Humans | Female | … | Bone density/drug effects |
|---|---|---|---|---|---|
| 1 | Humans | 4094 | 2703 | … | 78 |
| 2 | Female | 2703 | 2848 | … | 78 |
| 3 | Male | 2261 | 2115 | … | 50 |
| … | … | … | … | … | … |
| 90 | Bone Density/drug effects | 78 | 78 | … | 90 |
Centrality and density of the 5 clusters identified in this study.
| Cluster | Intra-class link average | Density-Y | Inter-class link average | Centrality-X |
|---|---|---|---|---|
| 0 | 260.04 | 174.07 | 44.62 | 18.44 |
| 1 | 38.31 | −47.67 | 10.43 | −15.75 |
| 2 | 57.36 | −28.61 | 27.66 | 1.48 |
| 3 | 36.13 | −49.84 | 21.92 | −4.27 |
| 4 | 38.03 | −47.95 | 26.30 | 0.11 |
| Average | 85.97 | 26.19 |
Figure 1Changes in the number of vitamin D-related papers (A) and journals (B) from 1997 to 2017.
Figure 2Visualized matrix of bi-clustering of highly frequent major MeSH terms and PubMed Unique Identifiers (PMIDs) of articles on vitamin D. The rows represent the high-frequency major MeSH terms, listed on the right. The bottom of the matrix shows the PMID for each source article.
Figure 3Mountain visualization of bi-clustering of highly frequent major MeSH terms and articles on vitamin D. The 90 high-frequency terms, listed on the right, are clustered in peaks that represent 5 clusters numbered from 0 to 4.
Figure 4Strategic diagram of the clusters.
Figure 5Vitamin D-related disease distribution from 2002 to 2005 (A) and from 2015 to 2018 (B). The numbers of publications are 707 (A) and 2351 (B), respectively.
Figure 6Vitamin D-related endocrine and metabolic system diseases (A) and neoplasms (B) distribution (2015–2018). The number of publications is 406 (A) and 242 (B), respectively.